

Novel Type I Diabetes Auto-Antigen-Diagnostic and Therapeutic Uses Thereof

Published date: Feb. 1, 2012

Technology description

Summary

A joint CU-National Jewish research team led by Kathryn Haskins and John Kappler has identified a series of peptides in chromogranin A (ChgA) that may be the antigen(s) for a group of highly diabetogenic CD4 T cell clones, including the well-studied BDC-2.5 clone. In particular, a natural cleavage product of ChgA appears to be the primary immunogenic peptide. The research team has also developed antibodies against this peptide. The peptides and the antibodies can be used as diagnostic tools for identifying T1D patients, and they may also provide therapeutic and prophylactic treatments for type I diabetes.

Institution

[University of Colorado](#)

联系我们



叶先生

电话 : 021-65679356

手机 : 13414935137

邮箱 : yeyingsheng@zf-ym.com